Table 2.
Baseline demographic, clinical and cognitive data for the final sample with imaging data
| CET (n = 19) | EST (n = 12) | t-statistic | p value | |||
|---|---|---|---|---|---|---|
| Mean (S.D.) | Range | Mean (S.D.) | Range | |||
| Age (years) | 25.5 (5.7) | 19.3–43.2 | 27.9 (5.5) | 20.6–36.3 | 1.17 | 0.25 |
| Emotion management performance (t-score) | 44.8 (8.7) | 28–63 | 47.8 (11.4) | 32–63 | 0.83 | 0.41 |
| CPZ eq (mg) | 287.8 (235.2) | 25.0–750.0 | 468.8 (364.4) | 100.0–1433.5 | 1.66 | 0.11 |
| Duration of illness (years) | 4.5 (2.7) | 0.3–9.2 | 4.1 (2.2) | 1.3–8.3 | −0.32 | 0.75 |
| IQ | 111.0 (7.7) | 97–125 | 115 (16.7) | 89–139 | 0.92 | 0.36 |
| CET | EST | χ2-statistic | p value | |||
| Site | 0.12 | 0.73 | ||||
| Boston | 4 | 4 | ||||
| Pittsburgh | 15 | 8 | ||||
| Sex | 0.77 | 0.38 | ||||
| Female | 4 | 3 | ||||
| Male | 15 | 9 | ||||
| Race | 0.71 | 0.70 | ||||
| African-American | 3 | 3 | ||||
| Caucasian | 14 | 7 | ||||
| Others | 2 | 2 | ||||
| Diagnosis | 1.31 | 0.25 | ||||
| Schizoaffective disorder | 3 | 4 | ||||
| Schizophrenia | 16 | 8 | ||||
Note: CPZ eq, chlorpromazine equivalence; IQ, Intelligence quotient estimate based on two-subtest form of the Wechsler Abbreviated Scale Intelligence 2nd Edition (WASI-II).